-The Hindu Building ‘capitalism with Indian characteristics’ means decisions cannot ignore concerns of voters and communities As the economy slows down and the rupee wilts, Manmohan Singh has bitten the ‘reforms’ bullet with both eyes on the credit rating agencies whose negative reports have done much to dampen the ‘animal spirits’ of investors, foreign and native. Last November, when the Congress party made a push to introduce foreign direct investment in multi-brand retail,...

-The Economic Times MUMBAI: In a victory to generic drugmakers, the Intellectual Property Appellate Board (IPAB) of Chennai has dismissed German pharma major Bayer's plea, seeking a stay on the Compulsory Licence issued to Hyderabad-based drugmaker Natco. The Compulsory Licence (CL) issued by the Controller of Patents in March this year allowed Natco to make and sell a generic version of Nexavar - used for treating liver and kidney cancer - at...

-The Telegraph Swiss pharma company Novartis today told the Supreme Court that if it gets an Indian patent on its anti-cancer drug Glivec, it would continue giving free drugs to 85 per cent patients till 2018 provided prices were left untouched. But the court described its scheme of classifying people on the basis of their incomes as “too complicated” and again urged the company to reduce prices. Whatever the scheme, the end result...

-Live Mint NAC wants Rashtriya Swasthya Bima Yojna to be absorbed into new policy for universal health coverage  The National Advisory Council (NAC), which sets the policy agenda for the Congress party led United Progressive Alliance (UPA) government, wants the Rashtriya Swasthya Bima Yojna (RSBY) insurance scheme to be absorbed into the new policy for universal health coverage (UHC), taking the latter closer to realization.   This is part of the government’s bid to move...

-Live Mint Cipla Ltd won a landmark patent case against Swiss drug maker F Hoffmann-La Roche Ltd in the Delhi high court on Friday over the Indian company’s generic copy of lung cancer drug Tarceva after a four-year court battle. Justice Manmohan Singh observed in his 280-page judgement that it had been scientifically proven that Cipla’s generic version was a polymorph B variant of Roche’s patented drug and that it didn’t actually...